Bayer shows staying power of hybrid corporate capital with Eu6bn of orders
Bayer, the German drugs and chemicals group, confirmed the remarkable rise to prominence of corporate hybrid capital this week, by issuing a Eu1.3bn bond that drew nearly Eu6bn of orders from 300 investors.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts